1-[4-(2-cyclopentyl-6,7-dihydro-5H-cyclopentapyrimidin-4-ylamino)-phenyl]-cyclobutanecarboxylic acid | 1215017-45-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[4-(2-cyclopentyl-6,7-dihydro-5H-cyclopentapyrimidin-4-ylamino)-phenyl]-cyclobutanecarboxylic acid
• 英文别名: 1-[4-[(2-cyclopentyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)amino]phenyl]cyclobutane-1-carboxylic acid
• CAS: 1215017-45-0
• 化学式: C₂₃H₂₇N₃O₂
• 分子量: 377.486
• InChiKey: NXKBDRPOTLECHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  75.1
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Novel Biccyclic Compounds As GATA Modulators
  申请人：De Dibyendu

  公开号：US20100144731A1

  公开（公告）日：2010-06-10

  Novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided. Additionally, methods of forming novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided.

  提供了新型双环化合物、立体异构体和/或新型双环化合物的药用可接受盐，以及新型双环化合物的立体异构体的药用可接受盐。此外，还提供了形成新型双环化合物、立体异构体和/或新型双环化合物的药用可接受盐，以及新型双环化合物的立体异构体的药用可接受盐的方法。
• US7989463B2
  申请人：——

  公开号：US7989463B2

  公开（公告）日：2011-08-02
• [EN] NOVEL BICCYCLIC COMPOUNDS AS GATA MODULATORS<br/>[FR] NOUVEAUX COMPOSÉS BICYCLIQUES COMME MODULATEURS DE GATA
  申请人：REDDYS LAB LTD DR

  公开号：WO2010028174A1

  公开（公告）日：2010-03-11

  Novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided. Additionally, methods of forming novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided.